head and neck cancer

Showing 5 posts of 5 posts found.

Merck building

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

March 1, 2021
Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …


First-line Keytruda shows better overall survival in head & neck cancer

October 23, 2018
Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …


Opdivo to go before EU, US regulators in head and neck cancer

July 19, 2016
Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo

Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …


Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …


Amgen’s Vectibix fails late stage trial

August 12, 2010
Research and Development, Sales and Marketing Amgen, Vectibix, head and neck cancer

Amgen’s potential head and neck cancer treatment Vectibix has failed to meet its primary endpoint of improving overall survival in …

Latest content